MSCs have many fascinating properties, including strong immunomodulatory effects, the ability to repair damaged tissues, and the capacity in vitro to differentiate into other cells types. These traits, combined with their easy availability from different sources, has prompted researchers to look at MSCs as promising raw materials for use in cell therapy, gene therapy, and tissue engineering, the three pillars of regenerative medicine. The cumulative efforts of scientists, researchers and life science companies have resulted in the approval of 12 MSC-based cell therapies (several of which have been approved in multiple regions) and 19 MSC-based bone matrices. [Read more…]
The Emerging Role of Regenerative Treatments in Diabetic Wound Care
Diabetes is a condition that affects millions worldwide, and one of its most challenging complications is the development of chronic wounds, including skin wounds and ulcers. These persistent wounds are not only painful and debilitating but also pose significant risks for infection and amputation. Traditional treatments often fall short, leading to the exploration of advanced regenerative therapies, including stem cells and exosomes, which have the potential to transform the management of these difficult conditions.
Companies are making significant strides in this field, and clinical trials are underway to test the effectiveness of these innovative approaches. [Read more…]
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells
GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed and proven to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cell (iPSC). [Read more…]
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials
Mytos’ iDEM platform replaces traditional iPSC manufacturing with a closed, automated system that delivers consistent, GMP-ready cells while reducing cost, variability, and time to clinic
Collaborations highlight the versatility of Mytos’ iDEM platform across diverse cell types and clinical applications from blindness and hearing loss to complex bone regeneration
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production
September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).
MSC-derived EVs are increasingly recognized as next-generation, cell-free therapeutic candidates, offering regenerative and immunomodulatory benefits without the safety concerns associated with administering intact MSCs. As the field shifts from MSC-based approaches to MSC-EVs, researchers are seeking solutions that deliver both robust yields and reproducible quality at scale. [Read more…]
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 202
- Next Page »